DE3104151C2 - - Google Patents
Info
- Publication number
- DE3104151C2 DE3104151C2 DE3104151A DE3104151A DE3104151C2 DE 3104151 C2 DE3104151 C2 DE 3104151C2 DE 3104151 A DE3104151 A DE 3104151A DE 3104151 A DE3104151 A DE 3104151A DE 3104151 C2 DE3104151 C2 DE 3104151C2
- Authority
- DE
- Germany
- Prior art keywords
- colonies
- agar
- nutrient medium
- medium
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000002609 medium Substances 0.000 claims description 36
- 235000015097 nutrients Nutrition 0.000 claims description 31
- 229920001817 Agar Polymers 0.000 claims description 27
- 235000010419 agar Nutrition 0.000 claims description 27
- 239000008272 agar Substances 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 22
- 229930013930 alkaloid Natural products 0.000 claims description 19
- 238000000855 fermentation Methods 0.000 claims description 17
- 230000004151 fermentation Effects 0.000 claims description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 239000001963 growth medium Substances 0.000 claims description 15
- 241000221751 Claviceps purpurea Species 0.000 claims description 13
- UJYGDMFEEDNVBF-UHFFFAOYSA-N Ergocorninine Natural products C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)C(C)C)C(C)C)C2)=C3C2=CNC3=C1 UJYGDMFEEDNVBF-UHFFFAOYSA-N 0.000 claims description 12
- 229950010031 beta-ergocryptine Drugs 0.000 claims description 12
- YYWXOXLDOMRDHW-UHFFFAOYSA-N beta-ergocryptine Natural products C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)C(C)CC)C(C)C)C2)=C3C2=CNC3=C1 YYWXOXLDOMRDHW-UHFFFAOYSA-N 0.000 claims description 12
- YYWXOXLDOMRDHW-SGVWFJRMSA-N β-ergocryptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)[C@@H](C)CC)C(C)C)C2)=C3C2=CNC3=C1 YYWXOXLDOMRDHW-SGVWFJRMSA-N 0.000 claims description 12
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002243 precursor Substances 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
- YDOTUXAWKBPQJW-UHFFFAOYSA-N alpha-Ergocryptinine Natural products C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=CNC3=C1 YDOTUXAWKBPQJW-UHFFFAOYSA-N 0.000 claims description 6
- YDOTUXAWKBPQJW-NSLWYYNWSA-N alpha-ergocryptine Chemical group C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=CNC3=C1 YDOTUXAWKBPQJW-NSLWYYNWSA-N 0.000 claims description 6
- 229950001817 alpha-ergocryptine Drugs 0.000 claims description 6
- 229960003133 ergot alkaloid Drugs 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000000908 ammonium hydroxide Substances 0.000 claims description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 5
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 210000003934 vacuole Anatomy 0.000 claims description 4
- WVVSZNPYNCNODU-CJBNDPTMSA-N Ergometrine Natural products C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-CJBNDPTMSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- WVVSZNPYNCNODU-XTQGRXLLSA-N Lysergic acid propanolamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-XTQGRXLLSA-N 0.000 claims description 3
- 150000003863 ammonium salts Chemical class 0.000 claims description 3
- 229960001405 ergometrine Drugs 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 238000009630 liquid culture Methods 0.000 claims description 3
- 239000001384 succinic acid Substances 0.000 claims description 3
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 claims description 2
- 150000004056 anthraquinones Chemical class 0.000 claims description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 238000012512 characterization method Methods 0.000 claims description 2
- 150000004338 hydroxy anthraquinones Chemical class 0.000 claims description 2
- 230000001788 irregular Effects 0.000 claims description 2
- 230000000050 nutritive effect Effects 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 229930015720 peptide alkaloid Natural products 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 230000028070 sporulation Effects 0.000 claims description 2
- XQUUDUKVJKNJNP-OGGGUQDZSA-N ergocornine Chemical compound C([C@H]1N(C)C2)C([C]34)=CN=C4C=CC=C3C1=C[C@H]2C(=O)N[C@@]1(C(C)C)C(=O)N2[C@@H](C(C)C)C(=O)N3CCC[C@H]3[C@]2(O)O1 XQUUDUKVJKNJNP-OGGGUQDZSA-N 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 1
- 239000002689 soil Substances 0.000 claims 1
- UJYGDMFEEDNVBF-OGGGUQDZSA-N ergocornine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)C(C)C)C(C)C)C2)=C3C2=CNC3=C1 UJYGDMFEEDNVBF-OGGGUQDZSA-N 0.000 description 7
- 235000010633 broth Nutrition 0.000 description 5
- XLMJRFCCCWFQRE-SJRQCXNHSA-N ecboline Chemical compound C([C@H]1[C@]2(O)O3)CCN1C(=O)CN2C(=O)[C@]3(C(C)C)NC(=O)[C@@H](CN(C)[C@@H]1C2)C=C1C1=C3C2=CNC3=CC=C1 XLMJRFCCCWFQRE-SJRQCXNHSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000221760 Claviceps Species 0.000 description 2
- NESVMZOPWPCFAU-UHFFFAOYSA-N Ergoclavinine Natural products C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)CC(C)C)C)C2)=C3C2=CNC3=C1 NESVMZOPWPCFAU-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NESVMZOPWPCFAU-ZPRCMDFASA-N ergosine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C)C2)=C3C2=CNC3=C1 NESVMZOPWPCFAU-ZPRCMDFASA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- QHZUABXEBRGBLP-LKWYKXIFSA-N (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-4-benzyl-9b-hydroxy-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-9b-hydroxy-3,5-dioxo-2,4-di(propan-2-yl)-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,10aR)-N-[(2S,4S,9bS)-9b-hydroxy-4-(2-methylpropyl)-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)C4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2CC(CN(C)[C@@H]2C2)C(=O)N[C@@]3(C(=O)C4[C@@H](C(N5CCCC5[C@@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(C21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 QHZUABXEBRGBLP-LKWYKXIFSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002908 adrenolytic effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 description 1
- SEALOBQTUQIVGU-QNIJNHAOSA-N dihydroergocornine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1 SEALOBQTUQIVGU-QNIJNHAOSA-N 0.000 description 1
- 229960004290 dihydroergocornine Drugs 0.000 description 1
- LIMAOLZSWRJOMG-HJPBWRTMSA-N dihydroergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C(C)C)C1=CC=CC=C1 LIMAOLZSWRJOMG-HJPBWRTMSA-N 0.000 description 1
- 229960004318 dihydroergocristine Drugs 0.000 description 1
- 229960002032 dihydroergocryptine Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- -1 ergocornine Chemical compound 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
- C12P17/183—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system containing an indolo[4,3-F,G]quinoleine nucleus, e.g. compound containing the lysergic acid nucleus as well as the dimeric ergot nucleus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/02—Ergot alkaloids of the cyclic peptide type
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU8080282A HU178405B (en) | 1980-02-08 | 1980-02-08 | Process for preparing ergocornine and beta-ergocryptine by fermentation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3104151A1 DE3104151A1 (de) | 1981-12-03 |
| DE3104151C2 true DE3104151C2 (en, 2012) | 1989-09-14 |
Family
ID=10948889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19813104151 Granted DE3104151A1 (de) | 1980-02-08 | 1981-02-06 | Zur mutterkornalkaloiderzeugung, insbesondere ergocornin- und (epsilon)-ergocryptinerzeugung, faehiger variantstamm und verfahren zur herstellung von mutterkornalkaloiden, insbesondere ergocornin und (epsilon)-ergocryptin |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4369252A (en, 2012) |
| JP (1) | JPS56158094A (en, 2012) |
| BE (1) | BE887391A (en, 2012) |
| CA (1) | CA1154699A (en, 2012) |
| CH (1) | CH648846A5 (en, 2012) |
| CS (1) | CS215148B2 (en, 2012) |
| DD (1) | DD156189A5 (en, 2012) |
| DE (1) | DE3104151A1 (en, 2012) |
| DK (1) | DK151274C (en, 2012) |
| FR (1) | FR2475573A1 (en, 2012) |
| GB (1) | GB2071651B (en, 2012) |
| HU (1) | HU178405B (en, 2012) |
| IL (1) | IL62079A (en, 2012) |
| IT (1) | IT1135359B (en, 2012) |
| NL (1) | NL8100567A (en, 2012) |
| SU (1) | SU1119609A3 (en, 2012) |
| YU (1) | YU27881A (en, 2012) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS222391B1 (en) * | 1981-07-28 | 1983-06-24 | Karin Strnadova | Microorganism strain of the claviceps purpurea /fr./ tul,ccm f-725 species |
| JPS58178988A (ja) * | 1982-04-14 | 1983-10-20 | 松下電器産業株式会社 | 調理器ユニツト |
| DE3420953A1 (de) | 1984-06-01 | 1985-12-05 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur herstellung von (alpha)-ergokryptin |
| WO2007051651A1 (en) * | 2005-11-07 | 2007-05-10 | Ivax Pharmaceuticals S.R.O. | INDUSTRIAL PRODUCING STRAIN OF THE FUNGUS CLAVICEPS PURPUREA (Fr.) Tul. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3884762A (en) * | 1972-04-21 | 1975-05-20 | Richger Gedeon Vegyeszeti Gyar | Fermentation process for the preparation of ergot alkaloids |
| IT1059516B (it) * | 1974-06-07 | 1982-06-21 | Farmaceutici Italia | Procedimento per la preparazione di beta-ergocriptina |
-
1980
- 1980-02-08 HU HU8080282A patent/HU178405B/hu not_active IP Right Cessation
-
1981
- 1981-02-03 YU YU00278/81A patent/YU27881A/xx unknown
- 1981-02-05 BE BE1/10131A patent/BE887391A/fr not_active IP Right Cessation
- 1981-02-05 CH CH774/81A patent/CH648846A5/de not_active IP Right Cessation
- 1981-02-06 SU SU813245499A patent/SU1119609A3/ru active
- 1981-02-06 US US06/232,172 patent/US4369252A/en not_active Expired - Fee Related
- 1981-02-06 CA CA000370248A patent/CA1154699A/en not_active Expired
- 1981-02-06 DK DK052581A patent/DK151274C/da not_active IP Right Cessation
- 1981-02-06 CS CS81912A patent/CS215148B2/cs unknown
- 1981-02-06 IL IL8162079D patent/IL62079A/xx unknown
- 1981-02-06 FR FR8102322A patent/FR2475573A1/fr active Granted
- 1981-02-06 NL NL8100567A patent/NL8100567A/nl not_active Application Discontinuation
- 1981-02-06 DE DE19813104151 patent/DE3104151A1/de active Granted
- 1981-02-06 IT IT19586/81A patent/IT1135359B/it active
- 1981-02-06 DD DD81227468A patent/DD156189A5/de not_active IP Right Cessation
- 1981-02-07 JP JP1738381A patent/JPS56158094A/ja active Pending
- 1981-02-09 GB GB8103853A patent/GB2071651B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2475573B1 (en, 2012) | 1984-04-27 |
| GB2071651A (en) | 1981-09-23 |
| IL62079A0 (en) | 1981-03-31 |
| JPS56158094A (en) | 1981-12-05 |
| IT1135359B (it) | 1986-08-20 |
| NL8100567A (nl) | 1981-09-01 |
| DK151274C (da) | 1988-06-20 |
| CS215148B2 (en) | 1982-07-30 |
| IT8119586A0 (it) | 1981-02-06 |
| DK151274B (da) | 1987-11-16 |
| DD156189A5 (de) | 1982-08-04 |
| DE3104151A1 (de) | 1981-12-03 |
| CA1154699A (en) | 1983-10-04 |
| IL62079A (en) | 1984-04-30 |
| GB2071651B (en) | 1983-10-19 |
| SU1119609A3 (ru) | 1984-10-15 |
| CH648846A5 (de) | 1985-04-15 |
| DK52581A (da) | 1981-08-09 |
| FR2475573A1 (fr) | 1981-08-14 |
| YU27881A (en) | 1983-10-31 |
| US4369252A (en) | 1983-01-18 |
| BE887391A (fr) | 1981-08-05 |
| HU178405B (en) | 1982-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2146400B2 (de) | Neuer biosynthetischer Wirkstoff, Verfahren zu seiner Herstellung und diesen Wirkstoff enthaltende Arzneimittelpräparate | |
| DE2306459A1 (de) | Pilzzuechtungsverfahren | |
| DE3104151C2 (en, 2012) | ||
| DE3127979A1 (de) | Verfahren zur erzeugung von cholesterase und deren anwendung | |
| DE3029348A1 (de) | Verfahren zur herstellung von l-asparaginsaeure | |
| CH662582A5 (de) | Verfahren zur erhoehung der antibiotikum-produktion durch in vivo genetische rekombination. | |
| EP0082114A1 (de) | Mikroorganismen des Genus Hyphomicrobium und Verfahren zum Abbau von Methylgruppen-haltigen Verbindungen in wässrigen Lösungen | |
| DE69102640T2 (de) | Verfahren zur herstellung von einer proteinhaltigen zusammensetzung. | |
| DE2035814A1 (de) | Neue Pleuromutihn Derivate und Ver fahren zu ihrer Herstellung | |
| EP0369029A1 (de) | Verfahren zur herstellung von l-alanin | |
| DE2428957C2 (de) | Verfahren zur Herstellung von Desacetoxycephalosporin C | |
| DE2239321A1 (de) | Herstellung von cephalosporin c | |
| DE2811303B2 (de) | Enzymatisch* Komplexe, die zur Umwandlung racemischer Hydantoine in optisch aktive Aminosäuren geeignet sind, sowie deren Anwendung | |
| DE2723463A1 (de) | Verfahren zur herstellung von 7-amino- cephem-verbindungen unter verwendung von schimmelpilzen | |
| DE2166462B2 (de) | 7 beta -(d-5-amino-5-carboxyvaleramido)-3-(alpha-methoxy-cinnamoyloxymethyl)-7-methoxy-3-cephem-4-carbonsaeure-verbindungen, verfahren zu ihrer herstellung und solche verbindungen enthaltende arzneimittel | |
| DE2638024C2 (de) | Verfahren zur Erhöhung der Cephamycin C-Ausbeute beim Züchten eines Cephamycin C erzeugenden Stammes der Gattung Streptomyces | |
| CH664758A5 (de) | Verfahren zur herstellung von clavin-mutterkornalkaloiden. | |
| DE2318650C2 (de) | Fermentative Herstellung von Deacetylcephalosporin C | |
| DE3006989C2 (en, 2012) | ||
| AT269363B (de) | Verfahren zur Herstellung eines Produktionsstammes einer Claviceps purpurea (Fr.) Tul.-Kultur zur Erzeugung von Mutterkornalkaloiden | |
| DE3881566T2 (de) | Antitumor-derivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. | |
| DE1517851C3 (de) | Verfahren zur Erhöhung der Alkaloidproduktion in submersen Claviceps-Kulturen | |
| DE2336765A1 (de) | Verfahren zur herstellung von mutterkornalkaloiden, vorzugsweise von ergokryptin und ergokornin, durch fermentation | |
| DE2921022C2 (en, 2012) | ||
| DE2319322A1 (de) | Verfahren zur herstellung von rifamycin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8180 | Miscellaneous part 1 |
Free format text: DIE BEZEICHNUNG LAUTET RICHTIG: ZUR MUTTERKORNALKALOIDERZEUGUNG, INSBESONDERE ERGOCORNIN- UND (BETA)-ERGOCRYPTINERZEUGUNG, FAEHIGER VARIANTSTAMM UND VERFAHREN ZUR HERSTELLUNG VON MUTTERKORNALKALOIDEN, INSBESONDERE ERGOCORNIN UND (BETA)-ERGOCRYPTIN |
|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |